Halozyme Therapeutics Inc. Stock
Halozyme Therapeutics Inc. shows a slight decrease today, losing -€0.520 (-0.960%) compared to yesterday.
The stock is one of the favorites of our community with 21 Buy predictions and 2 Sell predictions.
As a result the target price of 67 € shows a positive potential of 24.35% compared to the current price of 53.88 € for Halozyme Therapeutics Inc..
For the coming years our community has positive and negative things to say abot the Halozyme Therapeutics Inc. stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "Expected dividend yield" there were negative voices in the community.
Pros and Cons of Halozyme Therapeutics Inc. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
S********** s********
?
C******** o* t** e**********
Cons
?
B****
?
G***** c******* t* c**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Halozyme Therapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Halozyme Therapeutics Inc. | -0.960% | -11.430% | -7.828% | 18.829% | 19.037% | -0.965% | 62.777% |
| Ironwood Pharmaceuticals | 0.000% | -12.048% | 63.128% | -7.006% | -30.476% | -74.164% | -70.355% |
| Novocure Ltd | 1.730% | -6.222% | 10.076% | -60.710% | -64.286% | -85.491% | -91.736% |
| Iovance Biotherapeutics Inc. | -0.680% | -11.285% | -5.009% | -77.935% | -72.702% | -72.690% | -95.094% |
Comments
Halozyme Therapeutics (NASDAQ:HALO) had its "sell" rating reaffirmed by analysts at The Goldman Sachs Group, Inc.. They now have a $56.00 price target on the stock.
Show more
Ratings data for HALO provided by MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $90.00 price target on the stock.
Show more
Ratings data for HALO provided by MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) was upgraded by analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating.
Show more
Ratings data for HALO provided by MarketBeat
News
The Healthcare Sector Is Surging. Here's 1 Stock Every Investor Should Have on Their Radar.
Over the last three months, the S&P 500 healthcare sector has risen 13%, compared to the broader S&P 500 index's 7% increase.
However, one stock that hasn't matched its sector's returns is Halozyme
Renaissance Group Opens New $35M Position in Halozyme Therapeutics (NASDAQ: HALO): Why This Biotech Stock Is Worth a Look
On November 5, 2025, Renaissance Group LLC initiated a new position in Halozyme Therapeutics (NASDAQ:HALO), acquiring 478,735 shares for an estimated $35.11 million, according to a recent SEC
Halozyme (HALO) Q2 EPS Jumps 69%
Halozyme Therapeutics (NASDAQ:HALO), a biotechnology company specializing in drug delivery innovations, released its second-quarter 2025 results on August 5, 2025. The quarter’s headline is